Paul Hickey
President and Chief Executive Officer, Reshape Life Sciences
Replay available
ReShape Lifesciences, Inc. (RSLS) Q2 2023 Earnings Call
ReShape Lifesciences, Inc. (NASDAQ: RSLS) Q2 2023 earnings conference call, held 2023-08-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Christine Renfielding
Professor of Surgery, NYU Grossman School of Medicine; Director, NYU Langone Weight Management Program; Chief, Division of Bariatric Surgery
Tom Stankovich
Chief Financial Officer, Reshape Life Sciences
Anthony Vendetti
Analyst, Maxim Group
Unidentified Participant
Q&A Participant
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Vyome Holdings, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.029 -- 00:00:05.570 Good afternoon, and thank you for joining the Reshape Life Sciences second quarter 2023 00:00:05.570 -- 00:00:11.892 conference call. I would like to turn the call over to Michael Miller from RX Communications. 00:00:12.912 -- 00:00:16.793 Good afternoon, and thank you for joining the Reshape Life Sciences second quarter 2023 00:00:16.793 -- 00:00:21.995 earnings call. I'm pleased to be joined today by Paul Hickey, President and Chief 00:00:21.995 -- 00:00:26.516 Executive Officer, and Tom Stankovich, Chief Financial Officer. 00:00:26.516 -- 00:00:31.111 Paul will provide an overview and update on the company's activities which will include 00:00:31.111 -- 00:00:35.575 a discussion with Dr. Christine Renfielding, a member of Reshape Scientific Advisory 00:00:35.575 -- 00:00:39.678 Board. Then Tom will review the financial results for the period. 00:00:39.678 -- 00:00:44.363 He will then turn the call back over to Paul for some closing remarks, after which we'll 00:00:44.363 -- 00:00:47.265 open the call to a question and answer session. 00:00:47.265 -- 00:00:52.330 As a reminder, this conference call, as well as Reshape Life Sciences SEC filings 00:00:52.330 -- 00:00:57.434 and website, including the investor information section of the website, contains forward-looking 00:00:57.434 -- 00:01:02.797 statements within the meaning of the Private Securities Litigation Reform Act of 1995. 00:01:02.797 -- 00:01:07.559 Actual results could differ materially from those discussed due to known and unknown 00:01:07.559 -- 00:01:12.581 risks, uncertainties, and other factors. These and additional risk factors and 00:01:12.581 -- 00:01:17.303 uncertainties are described more fully in the company's filings with the Securities and 00:01:17.303 -- ...